Christoph Oing1,2, Christian Daniel Fankhauser3. 1. Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, NE1 7RU, Newcastle upon Tyne, Großbritannien. christoph.oing@newcastle.ac.uk. 2. Mildred Scheel Nachwuchszentrum HaTriCS4, Universitäres Cancer Center Hamburg, Universitätsklinikum Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland. christoph.oing@newcastle.ac.uk. 3. Klinik für Urologie, Kantonsspital Luzern, Luzern, Schweiz.
Abstract
BACKGROUND: Testicular germ cell tumours (GCTs) are the most frequent solid malignancy in younger males aged 15-40. The differentiation between seminomas and non-seminomas impacts prognosis, clinical management and follow-up procedures. With stage- and risk-adapted multimodal treatment approaches, GCTs have an exceptionally good prognosis. Therefore, avoiding overtreatment to reduce treatment-related long-term side effects is of utmost importance. Clinical and histopathological risk factors aid in treatment decision-making. OBJECTIVES: Discussion of (histo-)pathological characteristics that directly influence treatment decision-making by urologists and oncologists. MATERIALS AND METHODS: Non-systematic literature review to describe histopathological features for interdisciplinary treatment planning. RESULTS: Key histopathological characteristics for clinicians are: (i) identification of a GCT, if necessary by 12p aberration analysis, (ii) description of the different subtypes, and (iii) risk factors, including lymphovascular invasion and/or rete testis infiltration and size of the primary tumour. Molecular pathological analyses, that is, genomic sequencing, is not part of routine diagnostics due to the lack of prognostic/predictive markers and effective targeted treatment approaches. DISCUSSION: Detailed histopathology reporting, ideally with a synoptic template, is the basis for planning and conducting guideline-endorsed, risk-adapted, multi-disciplinary management of GCTs. Along with radiographic imaging and assessment of the serum tumour markers AFP and β‑HCG (especially in non-seminomas), histopathology is crucial to maintain success and reduce the burden of GCT treatment.
BACKGROUND: Testicular germ cell tumours (GCTs) are the most frequent solid malignancy in younger males aged 15-40. The differentiation between seminomas and non-seminomas impacts prognosis, clinical management and follow-up procedures. With stage- and risk-adapted multimodal treatment approaches, GCTs have an exceptionally good prognosis. Therefore, avoiding overtreatment to reduce treatment-related long-term side effects is of utmost importance. Clinical and histopathological risk factors aid in treatment decision-making. OBJECTIVES: Discussion of (histo-)pathological characteristics that directly influence treatment decision-making by urologists and oncologists. MATERIALS AND METHODS: Non-systematic literature review to describe histopathological features for interdisciplinary treatment planning. RESULTS: Key histopathological characteristics for clinicians are: (i) identification of a GCT, if necessary by 12p aberration analysis, (ii) description of the different subtypes, and (iii) risk factors, including lymphovascular invasion and/or rete testis infiltration and size of the primary tumour. Molecular pathological analyses, that is, genomic sequencing, is not part of routine diagnostics due to the lack of prognostic/predictive markers and effective targeted treatment approaches. DISCUSSION: Detailed histopathology reporting, ideally with a synoptic template, is the basis for planning and conducting guideline-endorsed, risk-adapted, multi-disciplinary management of GCTs. Along with radiographic imaging and assessment of the serum tumour markers AFP and β‑HCG (especially in non-seminomas), histopathology is crucial to maintain success and reduce the burden of GCT treatment.
Authors: Siamak Daneshmand; Peter Albers; Sophie Dorothea Fosså; Axel Heidenreich; Christian Kollmannsberger; Susan Krege; Craig Nichols; Jan Oldenburg; Lori Wood Journal: Eur Urol Date: 2012-08-20 Impact factor: 20.096
Authors: K Fizazi; J Oldenburg; A Dunant; I Chen; R Salvioni; J T Hartmann; M De Santis; G Daugaard; A Flechon; U de Giorgi; S Tjulandin; H J Schmoll; J Bouzy; S D Fossa; G Fromont Journal: Ann Oncol Date: 2007-11-27 Impact factor: 32.976
Authors: Kevin M Kernek; Matteo Brunelli; Thomas M Ulbright; John N Eble; Guido Martignoni; Shaobo Zhang; Helen Michael; Oscar W Cummings; Liang Cheng Journal: Mod Pathol Date: 2004-11 Impact factor: 7.842
Authors: J Oldenburg; D M Berney; C Bokemeyer; M A Climent; G Daugaard; J A Gietema; U De Giorgi; H S Haugnes; R A Huddart; R Leão; A Sohaib; S Gillessen; T Powles Journal: Ann Oncol Date: 2022-01-19 Impact factor: 32.976
Authors: Klaus-Peter Dieckmann; Hanna Simonsen-Richter; Magdalena Kulejewski; Petra Anheuser; Henrik Zecha; Hendrik Isbarn; Uwe Pichlmeier Journal: Biomed Res Int Date: 2019-05-28 Impact factor: 3.411